**Claims**

1. A method of stabilizing or decreasing body weight of a patient who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising administering by simple injection a last dose of the PP1M or the PP3M and then administering by simple injection an initial dose of a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).

2. The method of claim 1, wherein the patient has been treated with the PP1M for at least four months.

3. The method of claim 1 or 2, wherein the patient has been treated with the PP3M for at least one 3-month interval.

4. The method of any one of the preceding claims, wherein the initial dose of the PP6M is administered about 1 month (±7 days) after the last dose of the PP1M is administered.

5. The method of claim 4, wherein:
when the last dose of the PP1M comprises about 156 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate.

6. The method of claim 4, wherein:
when the last dose of the PP1M comprises about 234 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate.

7. The method of any one of the preceding claims, wherein the initial dose of the PP6M is administered about 3 months (±14 days) after the last dose of the PP3M is administered.

8. The method of claim 7, wherein:

when the last dose of the PP3M comprises about 546 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1092 mg of paliperidone palmitate.

9. The method of claim 7, wherein:

when the last dose of the PP3M comprises about 819 mg of paliperidone palmitate, the initial dose of the PP6M comprises about 1560 mg of paliperidone palmitate.

10. The method of any one of the preceding claims, wherein the patient has a body mass index (BMI) of about 25 to less than about 30 at the time of the initial dose of the PP6M.

11. The method of any one of the preceding claims, wherein the patient's body weight is assessed at the time of the initial dose of the PP6M.

12. The method of any one of preceding claims, wherein the patient is about 18 years old to about 25 years old.

13. The method of any one of the preceding claims, wherein the PP3M or PP6M comprises:

about 280 mg/mL to about 350 mg/mL of the paliperidone palmitate;
about 8 mg/mL to about 12 mg/mL of a wetting agent;
one or more buffering agents;
about 65 mg/mL to about 85 mg/mL of a suspending agent; and
water q.s. ad 100%.

14. The method of claim 13, wherein the PP3M or PP6M is from about pH 6.0 to about pH 8.0.

15. The method of claim 13 or claim 14, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

16. The method of claim 13, wherein the PP3M or PP6M comprises:

about 312 mg/mL of paliperidone palmitate;
about 10 mg/mL of polysorbate 20; and
about 75 mg/mL of polyethylene glycol 4000.

17. The method of any one of the preceding claims, wherein the PP1M comprises:
about 140 mg/mL to about 180 mg/ml of the paliperidone palmitate;
about 8 mg/mL to about 16 mg/ml of a wetting agent;
one or more buffering agents;
about 20 mg/mL to about 40 mg/ml of a suspending agent; and
water q.s. ad 100%.

18. The method of claim 17, wherein the PP1M is from about pH 6.0 to about pH 8.0.

19. The method of claim 17 or claim 18, wherein the one or more buffering agents comprise citric acid monohydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, or sodium hydroxide.

20. The method of claim 17, wherein the PP1M comprises:
about 156 mg/mL of paliperidone palmitate;
about 12 mg/mL of polysorbate 20; and
about 30 mg/mL of polyethylene glycol 4000.